Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001963213
Ethics application status
Approved
Date submitted
29/11/2018
Date registered
5/12/2018
Date last updated
13/12/2019
Date data sharing statement initially provided
5/12/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot study to assess the impact of obstructive sleep apnea (OSA) and treatment with continuous positive airway pressure (CPAP) therapy on maternal blood pressure and placental blood flow in high risk obstetric patients
Scientific title
A prospective cohort study to assess the impact of obstructive sleep apnea (OSA) and treatment with autotitrating continuous positive airway pressure (CPAP) therapy on maternal blood pressure and placental blood flow in severely obese obstetric patients
Secondary ID [1] 296739 0
None
Universal Trial Number (UTN)
U1111-1224-7149
Trial acronym
OSAP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obstructive sleep apnea 310608 0
Maternal hypertension 310611 0
Condition category
Condition code
Respiratory 309322 309322 0 0
Sleep apnoea
Reproductive Health and Childbirth 309323 309323 0 0
Antenatal care
Cardiovascular 309386 309386 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Autotitrating continuous airway pressure (CPAP) will be prescribed from a pressure of 4-20 cm H2O, for a minimum of 4 hours per night, to all pregnant women diagnosed with obstructive sleep apnea (as defined by an apnea-hypopnea index (AHI) of >10/hr) following a diagnostic polysomnogram and consultation with a sleep physician. Compliance to treatment will be individualized and assessed on a weekly basis by the sleep physician with the assistance of the sleep nurse and CPAP provider. Treatment with CPAP therapy will continue from the time of diagnosis of OSA up until 6 months post-partum following a repeat diagnostic sleep study.
Intervention code [1] 313046 0
Diagnosis / Prognosis
Intervention code [2] 313047 0
Treatment: Devices
Comparator / control treatment
Control group: pregnant patients with an early pregnancy body mass index (BMI) of 35 kg/m2 or more without OSA (as defined by an AHI of less than 10/hr)
Treatment group: pregnant patients with early pregnancy BMI of 35 kg/m2 or more with OSA (as defined by AHI of >10/hr) who will all be offered treatment with CPAP therapy
Control group
Active

Outcomes
Primary outcome [1] 308286 0
Maternal blood pressure control as measured by manual sphygmomanometer/digital blood pressure cuff at clinic visits and recorded in the patient's medical notes.
Timepoint [1] 308286 0
For the duration of pregnancy, recorded at every pregnancy clinic appointment (20 weeks, 28 weeks, 32 weeks, 38 weeks, delivery and at any additional outpatient clinic appointments during pregnancy)
Secondary outcome [1] 354537 0
Maternal quality of life as assessed by AQOL-8 and the sleep apnea specific version SAQLI
Timepoint [1] 354537 0
At enrollment prior to 28, at 32 weeks gestational age and 3 months post partum
Secondary outcome [2] 354538 0
Placental vascular health (as measured by arterial doppler)
Timepoint [2] 354538 0
28, 32 and 36 weeks gestation age
Secondary outcome [3] 354539 0
Placental vascular health (assessed following delivery by histopathology)
Timepoint [3] 354539 0
at delivery
Secondary outcome [4] 354540 0
Pregnancy complications as documented in pregnancy health record, via patient report or from medical records including: gestational diabetes, gestational hypertension, preeclampsia, preterm delivery, emergency ceasarean section, admission to ICCU, neonatal ICCU admission, APGAR scores at birth, neonatal birth weight
Timepoint [4] 354540 0
Until delivery
Secondary outcome [5] 354541 0
Persistence of obstructive sleep apnea as assessed by a repeat diagnostic polysomnogram
Timepoint [5] 354541 0
6 months post partum

Eligibility
Key inclusion criteria
Early pregnancy BMI of 35 kg/m2 or more
Gestational age less than 28 weeks
Ability to given informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Lack of regular attendance at clinic appointments
Illicit or intravenous drug use
Current cigarette smoking
Known diagnosis of OSA already established on CPAP therapy
Type 1 diabetes mellitus
Pulmonary hypertension
cardiomyopathy

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
A prospective cohort of high risk women will be followed during pregnancy and investigated for OSA. Those diagnosed with OSA will be offered treatment with CPAP therapy (non-randomized, non-blinded). All patienst will receive standard obstetric care for the duration of pregnancy and undergo maternal blood pressure assessment at regular clinic visits and ultrasound assessments at 28, 32 and 36 weeks gestational age.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
We anticipate a difference of 15 mmHg blood pressure readings between those participants who are compliant with CPAP therapy compared to those who are unable to tolerate this treatment. We estimate that a total sample of 58 participants with OSA (29 per group) completing the study would be sufficient to detect a post-treatment change in systolic blood pressure in the order of 15 mmHg between groups with 80% power and a 2-sided type I error of 0.05. This would be a modest and clinically important effect. Allowing for around ~10% attrition we have selected a total sample of 70 (35 per group). Should the effect size be smaller, this study would remain important for establishing feasibility and pilot data needed to help attract funding and refine study power for a larger study. We will use mixed effect model analysis in SPSS to test these hypotheses. This allows for repeated measures over time and adjustment for relevant co-variates.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
10/12/2018
Actual
2/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
70
Accrual to date
3
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 12598 0
Flinders Medical Centre - Bedford Park
Recruitment postcode(s) [1] 24972 0
5042 - Bedford Park

Funding & Sponsors
Funding source category [1] 301320 0
Hospital
Name [1] 301320 0
Flinders Medical Centre
Country [1] 301320 0
Australia
Primary sponsor type
Hospital
Name
Flinders Medical Centre
Address
2 Flinders Drive
Bedford Park SA
5046
Country
Australia
Secondary sponsor category [1] 300984 0
Commercial sector/Industry
Name [1] 300984 0
Philips SleepEasy Centre
Address [1] 300984 0
116-118 Beach Rd, Christies Beach SA 5165
Country [1] 300984 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302061 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 302061 0
Ethics committee country [1] 302061 0
Australia
Date submitted for ethics approval [1] 302061 0
09/04/2018
Approval date [1] 302061 0
17/05/2018
Ethics approval number [1] 302061 0
HREC/18/SAC/31 OFR number 28.18

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 88990 0
Dr Sarah Newhouse
Address 88990 0
Respiratory and Sleep Services
Flinders Medical Centre
2 Flinders Drive
Bedford Park, SA
5046
Country 88990 0
Australia
Phone 88990 0
+61 08 8204 5511
Fax 88990 0
+61 08 8204 5632
Email 88990 0
sarah.newhouse@sa.gov.au
Contact person for public queries
Name 88991 0
Sarah Newhouse
Address 88991 0
Respiratory and Sleep Services
Flinders Medical Centre
2 Flinders Drive
Bedford Park, SA
5046
Country 88991 0
Australia
Phone 88991 0
+61 08 8204 5511
Fax 88991 0
+61 08 8204 5632
Email 88991 0
sarah.newhouse@sa.gov.au
Contact person for scientific queries
Name 88992 0
Sarah Newhouse
Address 88992 0
Respiratory and Sleep Services
Flinders Medical Centre
2 Flinders Drive
Bedford Park, SA
5046
Country 88992 0
Australia
Phone 88992 0
+61 08 8204 5511
Fax 88992 0
+61 08 8204 5632
Email 88992 0
sarah.newhouse@sa.gov.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Patient confidentiality regarding CPAP adherence/pregnancy related complications which has not been included in the patient informed consent sheet


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
563Ethical approval    376483-(Uploaded-29-11-2018-12-19-01)-Study-related document.pdf
565Informed consent form    376483-(Uploaded-29-11-2018-12-19-34)-Study-related document.doc



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.